No One Missed: The Importance of Comprehensive Biomarker Testing in Non-Small Cell Lung Cancer

Lung cancer remains the leading cause of cancer death in both men and women in the US, with approximately 132,000 Americans being estimated to die from lung cancer in 2021. However, it also accounts for almost half of the overall decline in cancer mortality over the past five years. 1 This is largely due to advances in new lung cancer therapies, particularly precision medicines that target specific biomarkers. For a person living with lung cancer to benefit from these treatment advancements, their healthcare team must have all the important details regarding their unique tumor type. That is why comprehensive biomarker testing is so important for people living with non-small cell lung cancer (NSCLC).

AstraZeneca is proud to be the founding partner of a multi-year campaign called No One Missed, which aims to raise awareness about the importance of comprehensive biomarker testing in NSCLC. Joined by a number of high-profile pharmaceutical industry, patient advocacy partners and academic institutions, the LUNGevity Foundation-led campaign aims to encourage people diagnosed with NSCLC to talk to their healthcare team about comprehensive biomarker testing. The No One Missed campaign provides digital resources to help people living with NSCLC feel knowledgeable and confident when having these conversations.

While current guidelines recommend comprehensive biomarker testing, significant gaps remain between recommendation and use, potentially limiting the number of individuals receiving critical test results to help inform treatment decisions.2 This is where the No One Missed campaign hopes to have an impact: Increased awareness about the importance of comprehensive biomarker testing can help match people living with lung cancer with the appropriate treatment for their unique cancer.

"Lung cancer is a complex disease that requires an individualized approach in order to treat each patient's distinctive diagnosis," said Andrea Ferris, President and CEO of LUNGevity Foundation. "Every lung cancer patient has a right to be informed about comprehensive biomarker testing and to have a discussion with their healthcare team about a personalized treatment plan based on the results. No One Missed will help make certain that every person diagnosed with non-small cell lung cancer has a chance to pursue the best care."

AstraZeneca aims to lead a revolution in oncology to redefine cancer care by seeking to understand cancer and its complexities, treating diseases earlier and unleashing new treatments for precise targets to help ensure patients receive the right medicine at the right time. No One Missed helps reshape perceptions around biomarker testing and lung cancer treatment and reach one patient, one biomarker test at a time to create lasting change.

“We are proud to serve as a founding partner on No One Missed, which brings together stakeholders from across the lung cancer community – from industry to advocacy groups – committed to driving change for people living with non-small cell lung cancer,” said Chatrick Paul, SVP and Head of US Oncology at AstraZeneca. “Together, we can achieve more to help ensure patients receive comprehensive biomarker testing that can help inform treatment decisions as we aim to bring the right treatment to the right patient at the right time.”

The campaign website,, provides resources for patients and their caregivers to support their biomarker testing process, including a patient bill of rights and tips for talking to their healthcare team about biomarker testing.

Stay tuned for updates from AstraZeneca and LUNGevity as this campaign progresses.

1. American Cancer Society. Cancer Facts & Figures 2021. Atlanta: American Cancer Society; 2021

2. Gierman HJ, Goldfarb S, Labrador M, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(suppl; abstr 1585).